STATUS OF A T POLYMORPHISM IN EXON II OF KINASE INSERT DOMAIN GENE IN WOMEN WITH PREMATURE OVARIAN FAILURE
Journal Title: International Journal of Drug Regulatory Affairs - Year 2015, Vol 3, Issue 1
Abstract
Ovarian failure is defined as cessation of ovarian function under the age of 40 and it is characterized by amenorrhea hypo estrogenism and elevated gonadotrophin serum levels leading to infertility. Ovarian failure affects 1% of women. Causes of ovarian failure are extremely heterogenous. Ovarian failure is caused either by accelerated loss of eggs or the follicles themselves become less responsive to hormonal stimulation. It is high levels of gonadotrophins (luteinizing hormone and follicle stimulating hormone) hormonal defects may cause severe cardio vascular consequences and leads to the early onset of osteoporosis. Vascular endothelial growth factor (VEGF) is a major growth factor for endothelial cells. VEGF is involved in the process of angiogenesis for the development of Graffian follicle an important feature of growing follicle which has been arrested in the primordial follicular stage .VEGF mediates the process of angiogenesis through its receptors I and II.. Receptor II is known as Kinase insert domain receptor, is a type III receptor tyrosine Kinase.KDR is located at 4q11-q12.The main objective of this study was to screen the mutations in Kinase insert domain by using the techniques DNA isolation, Polymerase chain reaction and restriction fragment length polymorphism.
Authors and Affiliations
RGB Ali H. Hasan, Sujatha M
Keywords
Related Articles
- EP ID EP338285
- DOI -
- Views 91
- Downloads 0
DRUG PRODUCT REGISTRATION IN SEMI-REGULATED MARKET
There found a diversity of regulatory requirement in Semi regulated market. This region consists of mainly the countries from Asia pacific, Latin America, Eastern Europe, Africa and Gulf countries. Countries from Asia pa...
BIOBETTERS: THE BETTER BIOLOGICS AND THEIR REGULATORY OVERVIEW
The continuous innovation of the biopharmaceutical industry has led to development of a new category of biopharmaceuticals i.e. Biobetters or Biosuperiors. Biobetters may have better efficacy, a longer half-life, lower d...
Regulatory overview of biosimilars in Europe
A biosimilar is a biological medicine similar, but not identical, to an already registered reference bio therapeutic product in terms of quality, safety, and efficacy. These drugs are also called as biosimilar products„,...
Transnail drug delivery device:A prominent approach for Onychomycosis therapy
Onychomycosis is often challenging therapeutically and demands a multipronged approach both in terms of systemic as well as topical delivery. The conventional treatment modalities available for onychomycosis are marred w...
REGULATORY TECHNICALITIES FOR DRUG PRODUCT REGISTRATION IN BRAZIL
Brazilians are demanding better healthcare and modern medicines, presenting significant opportunities for foreign investment. In Brazil, medicinal product registration is an extensive process. To do business in Brazil is...